Perspective for Donor-Derived Cell-Free DNA in Antibody-Mediated Rejection After Kidney Transplantation: Defining Context of Use and Clinical Implications
Authors:
Open Access
- 12 August 2024
- journal article
- review article
- Published by Frontiers Media SA in Transplant International
- Vol. 37, 13239
Abstract
Antibody-mediated rejection (AMR) is a major cause of graft failure limiting long-term graft survival after kidney transplantation. Current diagnostic strategy to detect AMR is suboptimal and requires further improvement. Previously suggested treatment regimens for AMR could not demonstrate efficacy, however novel therapeutic agents are currently under investigation. Donor-derived cell-free DNA (dd-cfDNA) is a novel non-invasive biomarker for allograft injury, that has been mainly studied in the context of rejection. Its short-half-life in circulation and injury-dependent release are its key advantages that contribute to its superior diagnostic accuracy, compared to traditional biomarkers. Moreover, previous studies showed that dd-cfDNA-release is well-linked to histological and molecular features of AMR, and thus able to reflect real-time injury. Further observations suggest that dd-cfDNA can be used as a suitable screening tool for early detection of AMR in patients with donor-specific-anti-HLA-antibodies (DSA), as well as for monitoring AMR activity after anti-rejection treatment. The weight of evidence suggests that the integration of dd-cfDNA in the graft surveillance of patients with AMR, or those suspicious of AMR (e.g., due to the presence of donor-specific anti-HLA-antibodies) has an added value and might have a positive impact on outcomes in this specific cohort.Keywords
This publication has 83 references indexed in Scilit:
- Utility of Routine Post Kidney Transplant Anti-HLA Antibody ScreeningKidney International Reports, 2024
- Natural killer cell functional genetics and donor-specific antibody-triggered microvascular inflammationAmerican Journal of Transplantation, 2023
- Development and performance of a next generation sequencing (NGS) assay for monitoring of dd-cfDNA post solid organ transplantationClinica Chimica Acta, 2023
- The Banff 2022 Kidney Meeting Report: Reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnosticsAmerican Journal of Transplantation, 2023
- Donor-Derived Cell-Free DNA in Biopsy-Proven Antibody-Mediated Rejection Versus Recurrent IgA Nephropathy After Kidney TransplantationKidney International Reports, 2023
- Daratumumab for antibody-mediated rejection: Is it time to target the real culprit?American Journal of Transplantation, 2023
- Optimized immunosuppression to prevent graft failure in renal transplant recipients with HLA antibodies (OuTSMART): a randomised controlled trialeClinicalMedicine, 2023
- Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) studyKidney International, 2022
- Randomized clinical trial of a novel donor-derived cfDNA test to detect rejection in CPV-simulated renal transplant patientsInternational Urology and Nephrology, 2020
- Validation of a Clinical-Grade Assay to Measure Donor-Derived Cell-Free DNA in Solid Organ Transplant RecipientsThe Journal of Molecular Diagnostics, 2016